作者: William M. Ginn
DOI: 10.1001/JAMA.1966.03110240122045
关键词:
摘要: PROPRANOLOL hydrochloride (Inderal), a new beta adrenergic receptor blocking agent, apparently possessing potency ten to 20 times that of its predecessor, pronetalol,1yet lacking tumor producing qualities in mice,2recently has received clinical trial the treatment angina pectoris. Strivastava and associates3using propranolol, mg three daily double-blind study patients exhibiting pectoris, found no statistically significant difference frequency pectoris or nitroglycerin consumption. However, Keelan4in similar 19 but employing larger doses 30 daily, observed reduction number tablets used. Gillam Prichard,5utilizing maximum tolerated ceiling 100 four recorded improvement all 14 studied. The present paper reports results